GlaxoSmithKline PLC is looking to shake up Japan’s non-prescription allergy relief category with the launch of Flunase as the first fluticasone propionate-based treatment available OTC in the country.
With the same formulation and dosage as its prescription counterpart, Flunase was indicated to treat the major symptoms of allergic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?